0001209191-18-059445.txt : 20181120 0001209191-18-059445.hdr.sgml : 20181120 20181120164040 ACCESSION NUMBER: 0001209191-18-059445 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20181119 FILED AS OF DATE: 20181120 DATE AS OF CHANGE: 20181120 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Stankovic Srdjan R. CENTRAL INDEX KEY: 0001432545 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50768 FILM NUMBER: 181195982 MAIL ADDRESS: STREET 1: 35 NORTHEAST INDUSTRIAL ROAD CITY: BRANFORD STATE: CT ZIP: 06405 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 061376651 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3611 VALLEY CENTRE DRIVE STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-558-2871 MAIL ADDRESS: STREET 1: 3611 VALLEY CENTRE DRIVE STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-11-19 0 0001070494 ACADIA PHARMACEUTICALS INC ACAD 0001432545 Stankovic Srdjan R. C/O ACADIA PHARMACEUTICALS INC. 3611 VALLEY CENTRE DRIVE, STE. 300 SAN DIEGO CA 92130 0 1 0 0 President Employee Stock Options (Right to Buy) 18.12 2018-11-19 4 A 0 150000 0.00 A 2028-11-18 Common Stock 150000 150000 D Restricted Stock Units 2018-11-19 4 A 0 25000 0.00 A Common Stock 25000 25000 D 25% of the shares subject to the Stock Option vest and become exercisable on November 19, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. The restricted stock units vest in four equal annual installments beginning November 19, 2019. /s/ Austin D. Kim, Attorney-in-Fact 2018-11-20 EX-24.4_817990 2 poa.txt POA DOCUMENT POWER OF ATTORNEY Know all by these presents, that the undersigned hereby authorizes each of Austin D. Kim, Reena Desai, Eric Miller or Martin Choy to execute for and on behalf of the undersigned, in the undersigned's capacity as an officer of ACADIA Pharmaceuticals Inc. (the "Company"), Forms 3, 4 and 5 and any Amendments thereto, and cause such form(s) to be filed with the Securities and Exchange Commission pursuant to Section 16(a) of the Securities Exchange Act of 1934, relating to the undersigned's beneficial ownership of securities in the Company. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or substitute or substitutes of such attorney-in-fact, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the each such attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of, and transactions in, securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed this 19th day of November 2018. /s/ Srdjan R. Stankovic, M.D., M.S.P.H.